Veldurthy et al. [40] and our group [41] have both reported that dasatinib (primarily targeting LYN) generated a better in vitro apoptotic response in UM-CLL than M-CLL. This evidence concerns the gene LYN and B-cell chronic lymphocytic leukemia.